Teicoplanin Dosing Strategy for Treatment of Staphylococcus aureus in Korean Patients with Neutropenic Fever

被引:18
作者
Ahn, Byung-Jin [2 ]
Yim, Dong-Seok [3 ]
Lee, Dong-Gun [1 ]
Kwon, Jae-Cheol [1 ]
Kim, Si-Hyun [1 ]
Choi, Su-Mi [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701, South Korea
[2] Dongguk Univ, Grad Sch, Dept Med, Seoul, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Pharmacol, Seoul 137701, South Korea
关键词
Teicoplanin; Staphylococcus aureus; neutropenia; pharmacokinetics; pharmacodynamics; VANCOMYCIN; PHARMACODYNAMICS; PHARMACOKINETICS; GLYCOPEPTIDES; THERAPY; SYSTEM;
D O I
10.3349/ymj.2011.52.4.616
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The present study was conducted to determine and compare the target attainment rate (TAR) between microorganism-nonspecific (C-trough) and microorganism-specific (AUC(24)/MIC) targets over two weeks of teicoplanin administration according to several dose regimens for the treatment of Staphylococcus aureus in Korean patients with neutropenic fever. Materials and Methods: One thousand virtual concentrations were obtained for each dose using the population pharmacokinetic parameters of teicoplanin adopted from a published study. Simulation of 1,000 virtual MICs was performed using the MICs of 78 clinical isolates of S. aureus collected from a hospital in Korea. Thereafter, these simulated MICs were randomly allocated to 1,000 virtual patients in whom the TARs for AUC(24)/MIC >125 [or 345] and C-trough >10 [or 20] mg/L were determined. The relationship of the maintenance dose with the steady-state TAR was predicted with respect to the AUC(24)/MIC >125 [or 345] using logistic analysis. Results: The standard dose regimen of teicoplanin showed TARs of about 70% [or 33%] and 70% [or 20%] at steady-state in cases with AUC(24)/MIC >125 [or 345] and C-trough >10 [or 20] mg/L, respectively. Conclusion: The current standard dose regimen was predicted to be insufficient to adequately treat S. aureus in Korean patients with neutropenic fever. To assure at least an 80% TAR in this population, dose adjustment of teicoplanin should be considered.
引用
收藏
页码:616 / 623
页数:8
相关论文
共 26 条
[1]  
Clinical and Laboratory Standards Institute, 2006, M100S16 CLSI
[2]   Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid [J].
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :479-+
[3]   Variations of teicoplanin concentrations in neutropenic patients [J].
Gimenez, F ;
Leblond, V ;
Nguyen, J ;
Serrand, P ;
Binet, JL ;
Grosset, J ;
Thuillier, A .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1997, 22 (03) :187-190
[4]   Teicoplanin therapy for Staphylococcus aureus septicaemia:: relationship between pre-dose serum concentrations and outcome [J].
Harding, I ;
MacGowan, AP ;
White, LO ;
Darley, ESR ;
Reed, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :835-841
[5]   THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS [J].
HYATT, JM ;
MCKINNON, PS ;
ZIMMER, GS ;
SCHENTAG, JJ .
CLINICAL PHARMACOKINETICS, 1995, 28 (02) :143-160
[6]  
KORTING HC, 1999, BENEFIT RISK RATIO H
[7]   Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil [J].
Kuti, J. L. ;
Kiffer, C. R. V. ;
Mendes, C. M. F. ;
Nicolau, D. P. .
CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (02) :116-123
[8]  
Lee Dong-Gun, 2004, Infection and Chemotherapy, V36, P83
[9]   Population pharmacokinetic study of teicoplanin in severely neutropenic patients [J].
Lortholary, O ;
Tod, M ;
Rizzo, N ;
Padoin, C ;
Biard, O ;
Casassus, P ;
Guillevin, L ;
Petitjean, O .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1242-1247
[10]   Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia [J].
Lortholary, Olivier ;
Lefort, Agnes ;
Tod, Michel ;
Chomat, Anne-Marie ;
Darras-Joly, Clemence ;
Cordonnier, Catherine .
LANCET INFECTIOUS DISEASES, 2008, 8 (10) :612-620